Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1CNS 1

Conditions

Neoplasms 1Melanoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Brain Diseases 1

Interventions

Temozolomide 19Bevacizumab 14Irinotecan 12Carboplatin 10Cyclophosphamide 9Radiosurgery 8Lomustine 8Radiotherapy 7pembrolizumab 6Vincristine 6Topotecan 6Drug Therapy 6Surgical Procedures, Operative 5Etoposide 5Doxorubicin 5Cisplatin 53-Iodobenzylguanidine 5trametinib 4Metformin 4Gemcitabine 4Dexamethasone 4Blood Specimen Collection 4poly ICLC 3dabrafenib 3Vorinostat 3Trastuzumab 3Therapeutics 3Radiation 3Paclitaxel 3Observation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × PF-07284890 × CNS × Clear all
NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Pfizer

Phase 1 Terminated
65 enrolled 52 charts
CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡